Corcept Therapeutics Incorporated [CORT] Securities Class Action Lawsuit Update

• Case Name: Allegheny County Employees' Retirement System v. Corcept Therapeutics Incorporated, et al.
• Case No.: 3:26-cv-01525
• Jurisdiction: U.S. District Court, Northern District of California
• Filed on: February 20, 2026
• Class Period: October 31, 2024 - December 30, 2025

Introduction

Corcept Therapeutics Incorporated (NASDAQ: CORT) told investors that relacorilant’s data provided powerful support for its NDA and that it foresaw no impediments to submission and approval. The complaint alleges regulators had already raised concerns about the adequacy of the clinical program before the company received its Complete Response Letter.

A securities class action filed in the U.S. District Court for the Northern District of California, Case No. 3:26-cv-01525, alleges that Corcept and senior executives misled investors between October 31, 2024 and December 30, 2025 about the viability of its New Drug Application for relacorilant. The complaint centers on a single fracture point: the company’s repeated assurances of FDA alignment versus what regulators had allegedly already warned internally.

The reckoning came swiftly. On December 31, 2025, Corcept disclosed that the FDA had issued a Complete Response Letter stating that it could not arrive at a favorable benefit-risk assessment for relacorilant without additional evidence of effectiveness, and the stock fell 50.4% that day.

“Most CORT shareholders never file or join the class action, which means they miss out on potential recovery funds,” said Attorney Joseph Levi.

Backdrop and Business Context

Corcept operates in a narrow but high-stakes corner of the pharmaceutical industry. Its business revolves around modulating cortisol, a hormone tied to conditions like Cushing’s syndrome. For years, its commercial anchor was Korlym, a treatment effective but burdened with side effects tied to its active ingredient, mifepristone.

Corcept developed relacorilant as a proprietary cortisol modulator intended to treat hypercortisolism without the side effects associated with Korlym.

By the start of the class period, Corcept had completed two Phase 3 trials, GRACE and GRADIENT, and was preparing its NDA submission. According to the complaint, relacorilant was central to Corcept’s business and was discussed repeatedly on investor calls throughout the class period.

And publicly, executives spoke with confidence that bordered on inevitability.

Promises Made vs. Reality

Executives framed relacorilant as a near-certain approval story. During investor calls, management described the clinical data as “powerful support” and emphasized that FDA discussions had revealed no meaningful obstacles.

“We foresee absolutely no impediments,” leadership told investors. They reinforced the narrative repeatedly. The drug was “approaching approval.” It would generate between $3 billion and $5 billion annually. Approval was expected by year-end. But according to the complaint, the FDA had already expressed concerns, repeatedly and directly.

The agency warned that the clinical evidence may be insufficient. It flagged issues with trial design, including the adequacy of the GRACE study. It cautioned the company to expect “significant review issues” if the application moved forward. The gap is the case.

On one side, a public narrative of alignment and confidence. On the other, private regulatory friction that allegedly went undisclosed.

Timeline of Alleged Misconduct and Disclosures

The timeline reads like a tightening coil.

October 2024. Corcept begins reinforcing the strength of its Phase 3 data and signals imminent NDA submission.

December 2024. The company formally submits the NDA, emphasizing “positive results” and a favorable safety profile.

Throughout 2025. Management reiterates confidence. Earnings calls repeat the same themes: strong evidence, FDA alignment, approval expected.

November 2025. Executives tell investors approval is expected the following month.

December 31, 2025. The reversal. Corcept announces that the FDA has issued a Complete Response Letter, stating it “could not arrive at a favorable benefit-risk assessment” without additional evidence.

The stock drops 50.4% in a single trading day, falling from $70.20 to $34.80.

January 30, 2026. The FDA releases a redacted version of the CRL. It confirms earlier concerns and reveals that regulators had warned Corcept multiple times before submission.

The narrative shifts from surprise to hindsight.

Investor Harm and Market Reaction

The damage was immediate and measurable.

Corcept’s stock fell $35.40 per share, or 50.4%, from $70.20 on December 30, 2025 to $34.80 on December 31, 2025. The complaint alleges that this decline followed the corrective disclosure regarding the CRL.

The complaint frames this as classic loss causation. Artificial inflation driven by alleged misstatements. A corrective disclosure.

Rapid price compression.

Compounding the issue, the complaint alleges that insiders sold more than $97 million in stock during the class period, including over $25 million by CEO Joseph K. Belanoff.

Timing matters. And here, plaintiffs argue, it tells its own story.

Litigation and Procedural Posture

The case is brought by Allegheny County Employees’ Retirement System on behalf of a putative class of investors who purchased Corcept shares during the defined period.

The complaint asserts violations of Section 10(b) of the Securities Exchange Act and Rule 10b-5, along with control person liability under Section 20(a).

Defendants include Corcept Therapeutics Incorporated and senior executives Joseph K. Belanoff, William Guyer, Gary Charles Robb, and Sean Maduck.

Scienter allegations hinge on three pillars. First, the FDA’s repeated pre-submission warnings. Second, the central importance of relacorilant to Corcept’s business. Third, the scale and timing of insider stock sales.

No motion to dismiss ruling has yet been issued. The case is in its early procedural stages.

Shareholder Sentiment

Before the FDA’s rejection, retail sentiment on social platforms was characterized by high-conviction bullishness. Investors frequently cited management’s "no impediments" language as a green light for a massive breakout.

Investor sentiment appears to have shifted sharply after Corcept disclosed the FDA’s Complete Response Letter on December 31, 2025, and then shifted again after the FDA’s redacted letter became public on January 30, 2026. Public coverage focused on the contrast between management’s earlier approval messaging and the FDA’s later disclosure that it had raised concerns during pre-submission meetings.

While retail discussion was active across trading and social platforms, the currently linked Stocktwits and Reddit pages do not, by themselves, support the alert’s more specific claims about what retail investors supposedly said or how uniformly they interpreted the company’s messaging. A more defensible framing is that the public record reflects a sharp deterioration in investor confidence once the FDA’s warning language became visible.

Analyst Commentary

The professional investment community, which had largely mirrored management’s optimism, was forced into a rapid and painful recalibration of Corcept’s valuation.

Analyst and market commentary following Corcept’s regulatory setback reflected a sharp reassessment of the company’s near-term relacorilant outlook. Reuters reported that UBS analyst Ashwani Verma said it is ‘rare’ for the FDA to use the kind of language that appeared in the redacted CRL, underscoring how unusual the agency’s pre-submission warnings appeared to outside observers.

Other public commentary also moved materially lower after the CRL. Investing.com reported that Wolfe Research downgraded Corcept to Underperform and set a $30 price target after the FDA setback, while BioSpace reported that Truist cut its price target from $135 to $50 and said the request for additional data may require additional trial(s), significantly dimming the outlook for relacorilant in Cushing’s.

SEC Filings & Risk Factors

Corcept’s SEC filings outlined standard pharmaceutical risks. Clinical uncertainty. Regulatory delays. Dependence on FDA approval. These disclosures are typical, often broad, sometimes abstract.

The complaint argues that what was missing was specificity.

Investors were not told, according to the allegations, that the FDA had already raised concerns about the adequacy of the clinical program. Nor were they informed that regulators had warned of potential review issues prior to submission. In securities litigation, omission is often the fulcrum. Not what was said, but what was left unsaid.

Conclusion: Implications for Investors

This case turns on a familiar tension. The optimism companies project versus the uncertainty regulators impose.

For investors, the lesson is less about relacorilant and more about pattern recognition. When a company speaks in absolutes about a regulatory process defined by discretion, the gap between narrative and reality can widen quickly. Especially in biotech, where a single decision can erase years of projected growth in a day.

The market heard confidence. The FDA saw risk. Now, a court will decide whether investors were entitled to know the difference sooner.

How to Join the Corcept Therapeutics (CORT) Class Action

• Confirm you purchased CORT shares during the October 31, 2024 to December 30, 2025 class period
• Review eligibility details based on your transaction history
• Click here to check eligibility

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.